Rep. Bob Good

Maddy summaryHR 2191 blocks all funding for the Environmental Protection Agency's Hazardous Waste Electronic Manifest System in fiscal year 2024 by setting its available funds to $0. This bill directly affects the EPA's ability to operate this specific system, which tracks hazardous waste shipments electronically. The key mechanism is a strict prohibition on appropriating any funds for this system during FY2024, effectively halting its operation unless Congress passes new funding. As a procedural funding limitation, it does not change environmental regulations but prevents the system from functioning without new appropriations.

Maddy summaryHR 2241 sets a funding limit of $3,503,000 for the U.S. Department of Agriculture's Hazardous Materials Management program during fiscal year 2024. This bill directly restricts the amount of money the USDA can spend on managing hazardous materials under this specific program. It prevents the program from using funds exceeding this cap, applying only to the designated hazardous materials management activities within the USDA for that fiscal year.

This bill limits FY2024 funding for the Food and Drug Administration (FDA) Innovation Account, which the FDA uses to implement provisions of the 21st Century Cures Act relating to the development of medical products.

Maddy summaryHR 2296 sets a spending limit of $11,788,000 for building and facility projects at the Food and Drug Administration (FDA) and an unspecified "Related Agency" during fiscal year 2024. This bill directly restricts the budget available for infrastructure improvements at these two entities, capping all allocated funds for this purpose. The provision applies to all existing and future funding designated for these specific projects in the 2024 budget cycle. It does not alter FDA operations or regulations, only the financial allocation for physical facilities.

Maddy summaryThis bill sets a spending cap of $5.58 billion for the Food and Drug Administration (FDA) and related agencies within the Department of Health and Human Services (HHS) for fiscal year 2024. It directly affects the FDA's budget authority by restricting the total funds it can access during the fiscal year. The key provision is a hard limit on available funds, preventing the use of any amount exceeding $5,584,965,000. This is a straightforward budgetary restriction with no additional policy mechanisms or program changes.

Maddy summaryThe Safe Students Act (HR 2502) repeals the Gun-Free School Zones Act of 1990, which had prohibited possessing firearms in federally designated school zones under federal law. It also amends related sections of Title 18 (U.S. Code) to remove references to the repealed law and adjust section numbering. This bill does not establish a new federal rule for school zones; it solely eliminates the existing federal prohibition on firearms in school zones. The repeal means the federal government would no longer enforce this specific ban, though state laws may continue to regulate firearms in schools.

This joint resolution nullifies the final rule issued by the Consumer Financial Protection Bureau titled Small Business Lending under the Equal Credit Opportunity Act (Regulation B) and published on May 31, 2023. The rule requires financial institutions to collect and report to the bureau credit application data for small businesses. On July 31, 2023, the U.S. District Court for the Southern District of Texas ordered the bureau not to implement or enforce the rule until a related pending case is resolved.

Maddy summaryHR 1768, the NIH Reform Act, reorganizes the National Institutes of Health (NIH) by splitting the existing "National Institute of Allergy and Infectious Diseases" into three distinct institutes: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases. The bill updates titles, responsibilities, and leadership structures in the Public Health Service Act, including requiring presidential appointments with Senate confirmation for directors of the new institutes, each serving 5-year terms (with one possible reappointment). It mandates a transition period where the NIH Director oversees the new institutes until their directors are appointed, and updates all references to the former institute in federal law. This change directly affects NIH’s internal structure, leadership appointments, and administrative documentation, without altering research funding or policy priorities.

Maddy summaryHR 1911 sets a spending limit of $23,332,000 for "Joint Items" and the Capitol Visitors Center during fiscal year 2024. This bill directly affects funding allocations for these specific Capitol-related expenses by restricting the total amount that can be spent. The provision applies to all funds authorized for these purposes during FY2024, preventing any increase above the specified cap. It does not alter the function or services provided by the Capitol Visitors Center or the nature of "Joint Items."

Maddy summaryHR 1910 sets a spending limit of $14,759,000 for federal funding designated for "Joint Items" (shared agency projects) and the U.S. Botanic Garden during fiscal year 2024. This bill directly restricts how much money federal agencies can spend on these specific programs, preventing funds from exceeding the set cap. The key provision is a hard budget ceiling that applies to all available funds for these two categories in FY2024. It does not change program requirements or create new policies, only limiting the financial authorization.